Galen EB Wright

Latest

Characterisation of CYP2B6 and CYP2A6 pharmacogenetic variation in sub-Saharan African populations
A cross-sectional study of the relationship between CYP2D6 and CYP2C19 variations and depression symptoms, for women taking SSRIs during pregnancy
A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women
A systematic review and analysis of the use of polygenic scores in pharmacogenomics
Characterization of CYP2D6 Pharmacogenetic Variation in Sub-Saharan African Populations
Common huntingtin-related genetic variation is associated with neurobiological and aging traits in humans
Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis C
Integrating disease and drug-related phenotypes for improved identification of pharmacogenomic variants
Integrative neuroinformatics for precision prognostication and personalized therapeutics in moderate and severe traumatic brain injury
Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment
StellarPGx: A Nextflow pipeline for calling star alleles in cytochrome P450 genes
Transcriptome-wide association study uncovers the role of essential genes in anthracycline-induced cardiotoxicity
A systematic comparison of pharmacogene star allele calling bioinformatics algorithms: a focus on CYP2D6 genotyping
Frequency of the loss of CAA interruption in the HTT CAG tract and implications for Huntington disease in the reduced penetrance range
Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington disease
Huntington disease
Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies
Analyses of adverse drug reactions--nationwide active surveillance network: Canadian pharmacogenomics network for drug safety database
Genome-Wide Association Studies of Drug-Induced Liver Injury Make Progress Beyond the HLA Region
Length of uninterrupted CAG, independent of polyglutamine size, results in increased somatic instability, hastening onset of Huntington disease
Outcome definition influences the relationship between genetic polymorphisms of ERCC1, ERCC2, SLC22A2 and cisplatin nephrotoxicity in adult testicular cancer patients
Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research
Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes
Common variation near IRF6 is associated with IFN-$β$-induced liver injury in multiple sclerosis
CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines
Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer PatientsThe Role of ACYP2 and WFS1 in Cisplatin-Induced Ototoxicity
Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients
The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population
Association between SLC16A5 genetic variation and cisplatin-induced ototoxic effects in adult patients with testicular cancer
The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America
CYP2B6*6 and CYP2B6*18 predict long-term efavirenz exposure measured in hair samples in HIV-positive South African women
The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patients
Evaluation of predictive CYP2C19 genotyping assays relative to measured phenotype in a South African cohort
Considerations for rare variants in drug metabolism genes and the clinical implications
Informed consent and ethical re-use of African genomic data
Patterns of variation influencing antipsychotic treatment outcomes in South African first-episode schizophrenia patients
Sequencing of GJB2 in Cameroonians and Black South Africans and comparison to 1000 Genomes Project data support need to revise strategy for discovery of nonsyndromic deafness genes in Africans
Ethical and legal implications of whole genome and whole exome sequencing in African populations
Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study
Next-generation sequencing of pharmacogenes: a critical analysis focusing on schizophrenia treatment
Association of MB-COMT polymorphisms with schizophrenia-susceptibility and symptom severity in an African cohort
Chromosome 22q11 in a Xhosa schizophrenia population
End of the beginning and public health pharmacogenomics: knowledge in âMode 2âand P5 medicine
Pharmacogenomic research in South Africa: lessons learned and future opportunities in the rainbow nation
Whole-genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applications
Characterization of the genetic profile of CYP2C19 in two South African populations
Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population